# Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

> **NCT02595424** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 67 (actual)

## Conditions studied

- Gastric Neuroendocrine Carcinoma
- Intestinal Neuroendocrine Carcinoma
- Pancreatic Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02595424
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-11-06
- **Primary completion:** 2025-04-23
- **Final completion:** 2029-01-01
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595424, "Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02595424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*